Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Randomized Controlled Trial
37%
Placebo
37%
Miscarriage
33%
Progesterone
26%
Missed Abortion
26%
Misoprostol
26%
Mifepristone
26%
Uterine Artery Embolization
26%
Myomectomy
26%
Confidence Interval
22%
Cost-effectiveness
22%
Thyroid Peroxidase Antibody (TPOAb)
20%
Live Birth
20%
Levothyroxine
20%
Uterine Fibroids
20%
Misoprostol Alone
19%
Economic Evaluation
19%
Abnormal Uterine Bleeding
18%
Early Pregnancy Bleeding
17%
Pilot Randomized Controlled Trial
17%
People Experiencing Homelessness
17%
Community Pharmacy
17%
Euthyroid Women
13%
Early Pregnancy
12%
Randomized Placebo-controlled Trial
11%
Hysterectomy
11%
Postmenopausal Women
10%
Bleeding
10%
Placebo Groups
10%
Trying to Conceive
10%
Homeless Outreach
10%
Third Sector
10%
Levonorgestrel-releasing Intrauterine System (LNG-IUS)
10%
Independent Prescribing
10%
Non-medical
10%
Nulliparous Women
10%
Randomized Trial
9%
Polyps
8%
Estrogen Treatment
8%
Polypectomy
8%
Multicenter Trial
8%
Pelvic Organ Prolapse Surgery
8%
Estrogen
8%
Placebo-controlled Trial
8%
Euthyroid
8%
Hypothyroidism
8%
Oxytocin
8%
High Dose
8%
Lotus
8%
Atorvastatin
8%
Medicine and Dentistry
Randomized Controlled Trial
100%
Spontaneous Abortion
35%
Placebo
35%
Bleeding
29%
First Trimester Pregnancy
26%
Progesterone
26%
Uterine Artery Embolization
26%
Uterine Myomectomy
26%
Community Pharmacy
26%
Uterine Fibroid
22%
Quality of Life
19%
Nulliparous
18%
Cost-Effectiveness Analysis
18%
Misoprostol
17%
Mifepristone
17%
Drug Megadose
17%
Oxytocin
17%
Health Care Cost
17%
Menorrhagia
11%
Outpatient
11%
Hysterectomy
10%
Levonorgestrel
9%
Estrogen Therapy
8%
Gestagen
8%
Polyp
8%
Uterus Bleeding
8%
Endometriosis
8%
Recurrent Disease
8%
Postmenopause
8%
Pelvic Organ Prolapse
8%
Large Multicenter Trial
8%
Oral Contraceptive Agent
8%
Ulipristal
8%
Personal Experience
8%
Phase III Trials
8%
Human Immunodeficiency Virus
8%
Labor Stage 1
8%
Low Drug Dose
8%
National Health Service
8%
Polypectomy
8%
Cesarean Section
7%
Drug Dose Regimen
7%
Quality Adjusted Life Year
6%
Mifepristone Plus Misoprostol
5%
Clinical Trial
5%